Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials
| dc.contributor.author | Skapinakis, P. | en |
| dc.contributor.author | Bakola, E. | en |
| dc.contributor.author | Salanti, G. | en |
| dc.contributor.author | Lewis, G. | en |
| dc.contributor.author | Kyritsis, A. P. | en |
| dc.contributor.author | Mavreas, V. | en |
| dc.date.accessioned | 2015-11-24T19:20:23Z | |
| dc.date.available | 2015-11-24T19:20:23Z | |
| dc.identifier.issn | 1471-2377 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22036 | |
| dc.rights | Default Licence | - |
| dc.subject | Depressive Disorder/*complications/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Parkinson Disease/*complications/*drug therapy | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Serotonin Uptake Inhibitors/*therapeutic use | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials | en |
| heal.abstract | BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for the treatment of depression in patients with Parkinson's Disease (PD) but data on their efficacy are controversial. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials to investigate the efficacy and acceptability of SSRIs in the treatment of depression in PD. RESULTS: Ten studies were included. In the comparison between SSRIs and Placebo (n = 6 studies), the combined risk ratio (random effects) was 1.08 (95% confidence interval: 0.77 - 1.55, p = 0.67). In the comparison between SSRIs and Tricyclic Antidepressants (TCAs) (n = 3 studies) the combined risk ratio was 0.75 (0.39 - 1.42, p = 0.37). An acceptability analysis showed that SSRIs were generally well tolerated. CONCLUSIONS: These results suggest that there is insufficient evidence to reject the null hypothesis of no differences in efficacy between SSRIs and placebo in the treatment of depression in PD. Due to the limited number of studies and the small sample sizes a type II error (false negative) cannot be excluded. The comparison between SSRIs and TCAs is based on only three studies and further trials with more pragmatic design are needed. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1186/1471-2377-10-49 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20565960 | - |
| heal.identifier.secondary | http://www.biomedcentral.com/1471-2377/10/49 | - |
| heal.journalName | BMC Neurol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2010 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Πρωτότυπος φάκελος/πακέτο
1 - 1 of 1
Φόρτωση...
- Ονομα:
- Skapinakis-2010-efficacy and acceptability.pdf
- Μέγεθος:
- 2.22 MB
- Μορφότυπο:
- Adobe Portable Document Format
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: